MONEY

UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 30, 2024 - 20:00
UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis
Read More

Tags:

Previous Article

Perimeter Medical Imaging AI Announces Closing of Non-Brokered Private Placement

Next Article

China stocks surge on stimulus optimism, world stocks off record highs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Blinken says Russia received missiles from Iran, warns of threat to European security

Blinken says Russia received missiles from Iran, warns ...

Tomas Kauer - Mode... Sep 11, 2024

Bitcoin (BTC): Double Bottom or Head and Shoulders? Dogecoin (DOGE) Price Goes Through 5% Surge, Ethereum (ETH) at Pivotal Market Level

Bitcoin (BTC): Double Bottom or Head and Shoulders? Dog...

Tomas Kauer - Mode... Sep 27, 2024

Amplify Energy to Participate in the 2024 Citadel Securities Energy Investor Days

Amplify Energy to Participate in the 2024 Citadel Secur...

Tomas Kauer - Mode... Sep 14, 2024